Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
de Jong, Vincent M.T.; Pruntel, Roelof; Steenbruggen, Tessa G.; Bleeker, Fonnet E.; Nederlof, Petra; Hogervorst, Frans B.L.; linn, Sabine C.
(2023) Familial cancer, volume 22, issue 2, pp. 151 - 154
(Article)
Abstract
An inherited single nucleotide variant (SNV) in the 5′UTR of the BRCA1 gene c.-107A > T was identified to be related to BRCA1 promoter hypermethylation and a hereditary breast and ovarian cancer phenotype in two UK families. We investigated whether this BRCA1 variant was also present in a Dutch cohort
... read more
of breast and ovarian cancer patients with tumor BRCA1 promoter hypermethylation. We selected all breast and ovarian cancer cases that tested positive for tumor BRCA1 promoter hypermethylation at the Netherlands Cancer Institute and Sanger sequenced the specific mutation in the tumor DNA. In total, we identified 193 tumors with BRCA1 promoter hypermethylation in 178 unique patients. The wild-type allele was identified in 100% (193/193) of sequenced tumor samples. In a large cohort of 178 patients, none had tumors harboring the previously identified c.-107A > T SNV in BRCA1. We therefore can conclude that the germline SNV is not pervasive in patients with tumor BRCA1 promoter hypermethylation.
show less
Download/Full Text
Keywords: BRCA1, Breast cancer, Methylation, Genetics(clinical), Genetics, Oncology, Cancer Research, Journal Article
ISSN: 1389-9600
Publisher: Springer Netherlands
Note: Funding Information: SCL reports grants from ZonMw, the Dutch Cancer Society, and A Sister’s Hope during the conduct of the study. SCL is an advisory board member for Cergentis, and IBM, and received institutional research support from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, Novartis, Pfizer, Roche, Tesaro, and Immunomedics. In addition, SCL received institutional non-financial support from AstraZeneca, Genentech, Novartis, Roche, Tesaro, and Immunomedics and institutional educational financial support from Bayer and Daiichi-Sankyo outside of this study. All other authors declare no competing interest. Publisher Copyright: © 2022, The Author(s).
(Peer reviewed)